Buckingham Palace announced April 26 that the royal monarch will return to public-facing duties "after a period of treatment and recuperation" following his recent cancer diagnosis.
Charles and Queen Camilla will make a joint visit to a cancer treatment center April 30, where they will meet medical specialists and patients, according to the palace, who also noted that this outing "will be the first in a number of external engagements His Majesty will undertake in the weeks ahead."
The couple also plans to host the Emperor and Empress of Japan for a State Visit in June.
Additionally, as the first anniversary of Charles' coronation approaches, the statement noted that the royals "remain deeply grateful for the many kindnesses and good wishes they have received from around the world throughout the joys and challenges of the past year."
A spokesperson for the palace also shared an update on the 75-year-old's health, stating that His Majesty is "greatly encouraged to be resuming some public-facing duties and very grateful to his medical team for their continued care and expertise."
And although Charles' treatment program will continue, his doctors are sufficiently pleased with the progress made so far.
"Forthcoming engagements will be adapted where necessary," the spokesperson noted, "to minimize any risks to His Majesty's continued recovery."
This health update comes nearly three months after Charles' diagnosis was shared with the public.
"During The King's recent hospital procedure for benign prostate enlargement, a separate issue of concern was noted," a February statement from Buckingham Palace read. "Subsequent diagnostic tests have identified a form of cancer. His Majesty has today commenced a schedule of regular treatments, during which time he has been advised by doctors to postpone public-facing duties."
Donald Trump and his allies have made new tariffs into a centerpiece of his potential second term economic agenda. They are openly exploring legally-untested options for making them a reality.
Samsung Medison, a medical device unit of Samsung Electronics that specializes in developing diagnostic imaging devices, said on Wednesday it plans to acquire Sonio, a Paris-based startup that makes AI-powered software for ultrasound workflows, for about $92.7 million (KRW 126 billion). The French startup's AI assistant is aimed at helping obstetricians and gynecologists with the evaluation and documentation of ultrasound exams, and it has also received regulatory clearance in the United States (FDA 510(k)) for Sonio Detect, a product that uses deep learning algorithms to improve the image quality of ultrasound scans in real time. Samsung Medison said Sonio's software would help it bring better AI-driven imaging workflows to the market.
With free agency and the draft behind us, what 32 teams look like today will likely be what they look like Week 1 and beyond for the 2024 season. Matt Harmon and Scott Pianowski reveal the post-draft fantasy power rankings. The duo break down the rankings in six tiers: Elite offensive ecosystems, teams on the cusp of being complete mixed bag ecosystems, offensive ecosystems with something to prove, offenses that could go either way, and offenses that are best to stay away from in fantasy.
On today's episode of The Exempt List, Charles McDonald is joined by ESPN's Miami Dolphins reporter Marcel Louis-Jacques to break down Tua Tagovailoa's upcoming contract negotiation, the Kendrick Lamar vs Drake beef, and the Tom Brady Roast.
Apple just announced a new version of its popular video editing suite Final Cut Pro for iPad. There’s also a refresh for Mac and a new Logic Pro app for iPad.